Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510159 | 0.79 | HDAC6 (0.52) | TAS1R3TAS1R1LMNATP53NPC1 | |
| SCHEMBL6506293 | 0.77 | HDAC1 (0.58) | MAOBTP53NPC1RAB9AMEN1 | |
| SCHEMBL6506238 | 0.76 | LMNA (0.46) | LMNATP53NPC1RAB9AMEN1 | |
| SCHEMBL6512229 | 0.74 | TP53 (0.40) | TAS1R3TAS1R1LMNATP53RAB9A | |
| SCHEMBL6510152 | 0.74 | HDAC2 (0.52) | LMNATP53NPC1RAB9AMEN1 | |
| SCHEMBL6514847 | 0.74 | TP53 (0.40) | TAS1R3TAS1R1LMNATP53NPC1 | |
| SCHEMBL6507649 | 0.74 | HDAC1 (0.46) | MAOBLMNATP53NPC1RAB9A | |
| SCHEMBL6513479 | 0.73 | ALDH1A1 (0.54) | MAOAMAOBTP53NPC1RAB9A | |
| SCHEMBL6510896 | 0.73 | ROCK1 (0.50) | LMNANPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL6511335 | 0.73 | KMT2A (0.57) | LMNATP53NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | MAOA 1890/4885MAOB 1665/4885TAS1R3 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.